Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-05T10:50:31.056Z.
Calculation as of: 2026-10-05T10:50:31.056Z.
Quote observation: 2026-10-02T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 49eba324224a3154c2946aeaa7b2ea8ca99dc2d017fdd5025060ec0ea8a52c68
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hinge Health, Inc. (HNGE) | $7.56B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.02B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.63B | N/A | 2.98 | 2.74 | 2.10 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.47B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.12B | 0.24 | 0.59 | 0.53 | 0.53 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.61B | N/A | N/A | N/A | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.67B | 7.83 | 7.70 | 5.58 | 3.64 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.35B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.22B | 0.63 | 0.44 | 0.41 | 0.41 |
| Molina Healthcare, Inc. (MOH)vs › | $9.89B | N/A | 0.97 | 1.22 | 0.90 |
PEG Ratio
N/A
P/E Ratio
75.9
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
